How we prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies - PubMed
3 hours ago
- #bispecific antibodies
- #infection prevention
- #hematologic malignancies
- T-cell engaging bispecific antibodies (BsAbs) are widely used for hematologic malignancies but lead to new infection risks.
- Infections are frequent and the main cause of non-relapse mortality due to immune suppression from BsAbs.
- Risk factors include B-cell/plasma-cell aplasia, hypogammaglobulinemia, cytopenias, T-cell exhaustion, and cytokine modulation.
- A phased framework for infection prevention covers pre-treatment, active therapy, and long-term follow-up.
- Strategies include screening, antimicrobial prophylaxis, immunoglobulin supplementation, vaccination, and supportive care.